Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study.
The use of vancomycin as part of the initial antibiotic therapy of febrile neutropenic patients has become a controversial issue. Some studies support its incorporation in the initial regimen, and others suggest that vancomycin can be added later. We examined this issue in a prospective, randomized...
Saved in:
| Published in: | Antimicrob Agents Chemother |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
American Society for Microbiology (ASM)
1992
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC188836/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/1510394/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.36.5.1062 |
| Tags: |
No Tags, Be the first to tag this record!
|